New Alzheimer's drug: 'Benefits confirmed'
By Leroy Leo and Khushi Mandowara - U.S. Food and Drug Administration staff on Wednesday said data from a late-stage trial of Eisai and Biogen's Alzheimer's disease drug suggests it offered a meaningful benefit to patients and safety concerns likely would not hamper its chances of a traditional approval.
Analysts said the documents seemed to suggest approval for the drug. The FDA decision is expected by July 6. Eisai's application for a full approval is based on data showing Leqembi slowed the rate of cognitive decline in patients with early Alzheimer's by 27% compared to a placebo. The staff asked panelists to discuss the risk of serious side effects associated with the use of Leqembi in patients with a hard to diagnose condition called cerebral amyloid angiopathy, in which the protein amyloid that the drug targets builds up in the walls of arteries in the brain.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eisai-Biogen Alzheimer's drug data confirms benefits, FDA staff saysU.S. Food and Drug Administration staff on Wednesday said data from a late-stage trial of Eisai and Biogen's Alzheimer's disease drug suggests it offered a meaningful benefit to patients and safety concerns likely would not hamper its chances of a traditional approval.
Read more »
Alzheimer's drug gives hope, Sevenoaks family saysDavid Essam started developing Alzheimer's about seven years ago and was put on a drugs trial.
Read more »
Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take actionSen. Bernie Sanders said the $26,500 annual price for Alzheimer's treatment Leqembi would financially burden on Medicare and increase premiums for seniors.
Read more »
Tactile stimulation at 40 Hz may help in Alzheimer's treatmentNew MIT study says whole-body stimulation improved motor performance, reduced phosphorylated tau, preserved neurons and synapses, and reduced DNA damage.
Read more »
Alzheimer’s advocates rally for Medicare coverage of newly approved FDA treatmentsNew treatments for Alzheimer’s are on the market, but the price tag is making them inaccessible. The new treatments are not covered by Medicare or Medicaid, which is something the Alzheimer’s Association is trying to change.
Read more »
Brain-boosting foods for fighting memory loss, preventing Alzheimer’s diseaseThere are several foods such as berries, spinach and even chocolate that promote healthy brain function. Incorporating these foods into your diet could help your memory.
Read more »